Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19-tTreg in R/R B-ALL
NCT05114837Phase 2Withdrawn
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2024
- Primary completion
- Aug 2028
- Modality
- Regulatory T Cells (Tregs), CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAR19-tTreg in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Masonic Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and CAR19-tTregs efficacy at 28 days. Planned start Sep 2024; status: withdrawn.
02
Drugs
CAR19-tTreg
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05114837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114837.